These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 15378479

  • 1. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma.
    Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, Argani P, Hidalgo M, Iacobelli S, Goggins M, Maitra A.
    Cancer; 2004 Oct 01; 101(7):1609-15. PubMed ID: 15378479
    [Abstract] [Full Text] [Related]

  • 2. Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases.
    Enjoji M, Yamaguchi K, Nakamuta M, Nakashima M, Kotoh K, Tanaka M, Nawata H, Watanabe T.
    Dig Liver Dis; 2004 Sep 01; 36(9):622-7. PubMed ID: 15460847
    [Abstract] [Full Text] [Related]

  • 3. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis.
    Lindberg B, Arnelo U, Bergquist A, Thörne A, Hjerpe A, Granqvist S, Hansson LO, Tribukait B, Persson B, Broomé U.
    Endoscopy; 2002 Nov 01; 34(11):909-16. PubMed ID: 12430077
    [Abstract] [Full Text] [Related]

  • 4. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
    Scarlett CJ, Saxby AJ, Nielsen A, Bell C, Samra JS, Hugh T, Baxter RC, Smith RC.
    Hepatology; 2006 Sep 01; 44(3):658-66. PubMed ID: 16941699
    [Abstract] [Full Text] [Related]

  • 5. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, Seo DW, Lee SK, Min YI.
    Am J Gastroenterol; 1999 Jul 01; 94(7):1941-6. PubMed ID: 10406263
    [Abstract] [Full Text] [Related]

  • 6. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
    Lempinen M, Isoniemi H, Mäkisalo H, Nordin A, Halme L, Arola J, Höckerstedt K, Stenman UH.
    J Hepatol; 2007 Nov 01; 47(5):677-83. PubMed ID: 17640760
    [Abstract] [Full Text] [Related]

  • 7. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
    Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F.
    Am J Surg; 2009 Sep 01; 198(3):333-9. PubMed ID: 19375064
    [Abstract] [Full Text] [Related]

  • 8. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
    Akdoğan M, Parlak E, Kayhan B, Balk M, Saydam G, Sahin B.
    Turk J Gastroenterol; 2003 Sep 01; 14(3):181-4. PubMed ID: 14655062
    [Abstract] [Full Text] [Related]

  • 9. Impact of dominant stenoses on the serum level of the tumor marker CA19-9 in patients with primary sclerosing cholangitis.
    Petersen-Benz C, Stiehl A.
    Z Gastroenterol; 2005 Jun 01; 43(6):587-90. PubMed ID: 15986288
    [Abstract] [Full Text] [Related]

  • 10. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
    Nakeeb A, Lipsett PA, Lillemoe KD, Fox-Talbot MK, Coleman J, Cameron JL, Pitt HA.
    Am J Surg; 1996 Jan 01; 171(1):147-52; discussion 152-3. PubMed ID: 8554130
    [Abstract] [Full Text] [Related]

  • 11. Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis.
    Albiin N, Smith IC, Arnelo U, Lindberg B, Bergquist A, Dolenko B, Bryksina N, Bezabeh T.
    Acta Radiol; 2008 Oct 01; 49(8):855-62. PubMed ID: 18608012
    [Abstract] [Full Text] [Related]

  • 12. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
    Ohshio G, Manabe T, Watanabe Y, Endo K, Kudo H, Suzuki T, Tobe T.
    Am J Gastroenterol; 1990 Oct 01; 85(10):1370-6. PubMed ID: 2220731
    [Abstract] [Full Text] [Related]

  • 13. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels.
    Furmanczyk PS, Grieco VS, Agoff SN.
    Am J Clin Pathol; 2005 Sep 01; 124(3):355-60. PubMed ID: 16191503
    [Abstract] [Full Text] [Related]

  • 14. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Wannhoff A, Hov JR, Folseraas T, Rupp C, Friedrich K, Anmarkrud JA, Weiss KH, Sauer P, Schirmacher P, Boberg KM, Stremmel W, Karlsen TH, Gotthardt DN.
    J Hepatol; 2013 Dec 01; 59(6):1278-84. PubMed ID: 23958938
    [Abstract] [Full Text] [Related]

  • 15. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar 01; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 16. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis.
    Lankisch TO, Metzger J, Negm AA, Vosskuhl K, Schiffer E, Siwy J, Weismüller TJ, Schneider AS, Thedieck K, Baumeister R, Zürbig P, Weissinger EM, Manns MP, Mischak H, Wedemeyer J.
    Hepatology; 2011 Mar 01; 53(3):875-84. PubMed ID: 21374660
    [Abstract] [Full Text] [Related]

  • 17. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran V, Logsdon CD.
    Pancreas; 2007 May 01; 34(4):436-43. PubMed ID: 17446843
    [Abstract] [Full Text] [Related]

  • 18. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
    Mann DV, Edwards R, Ho S, Lau WY, Glazer G.
    Eur J Surg Oncol; 2000 Aug 01; 26(5):474-9. PubMed ID: 11016469
    [Abstract] [Full Text] [Related]

  • 19. A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.
    Sandanayake NS, Sinclair J, Andreola F, Chapman MH, Xue A, Webster GJ, Clarkson A, Gill A, Norton ID, Smith RC, Timms JF, Pereira SP.
    Br J Cancer; 2011 Oct 25; 105(9):1370-8. PubMed ID: 21970875
    [Abstract] [Full Text] [Related]

  • 20. Fibronectin in human bile fluid for diagnosis of malignant biliary diseases.
    Körner T, Kropf J, Hackler R, Brenzel A, Gressner AM.
    Hepatology; 1996 Mar 25; 23(3):423-8. PubMed ID: 8617420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.